“The successful design and analysis of the data from the allo-octoploid strawberry genome was possible only because of the expertise, commitment, and collaborative efforts of the Axiom myDesign custom array, bioinformatics, and product support teams within Affymetrix,” stated Eric van de Weg. “It is awesome to have the tools to construct such high marker-density maps generated in such a short time. We expect this array to be a valuable resource for genome-wide analysis and marker-assisted breeding in many American, European and other breeding programs.”“Genotyping the octoploid strawberry genome demonstrates the power and precision of the Axiom Genotyping platform to type genetic variants within complex genomes,” said Andy Last, Executive Vice President of the Genetic Analysis Business Unit at Affymetrix. “The array design process and updates to the automated analysis software used with Axiom Strawberry Genotyping Array are significant milestones for our platform because they enable the worldwide plant and animal genotyping community to leverage the Axiom myDesign customization process and analysis software to genotype even more species of interest.” Axiom Strawberry Genotyping Array will complement the catalog of Axiom Agrigenomics Genotyping Arrays that are available for multiple species, including bovine, chicken, and buffalo. These products have been used for genome-wide association studies, quantitative trait locus mapping, genome mapping, and breeding activities that make use of marker-assisted selection and genomic selection. As scientists make progress in decoding genomes of various plants, animals, and fish using next-generation sequencing platforms, they can advance their research and commercial objectives by translating those discoveries to routine applications on the Axiom Genotyping platform. To learn more about Axiom Genotyping Solutions, please visit www.affymetrix.com/axiom for applications in human diseases research and www.affymetrix.com/agrigenotyping for applications in agrigenomics. PLEASE NOTE: Affymetrix, the Affymetrix logo, Axiom, and all other trademarks are the property of Affymetrix, Inc. All other trademarks are the property of their respective owners. Forward-looking statements All statements in this press release that are not historical are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix' "expectations," "beliefs," "hopes," "intentions," "strategies," or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected. These and other risk factors are discussed in Affymetrix' Form 10-K for the year ended December 31, 2012, and other SEC reports for subsequent quarterly periods.
About AffymetrixAffymetrix technologies enable multiplex and simultaneous analysis of biological systems at the cell, protein, and gene level, facilitating the rapid translation of bench-top research into clinical and routine use for human health and wellness. We strive to provide leadership and support, partnering with our customers in pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government, and non-profit research institutes in their quest for answers toward using biology for a better world. More than 2,300 microarray systems have been shipped around the world and more than 48,000 peer-reviewed papers have been published citing our technologies. Affymetrix is headquartered in Santa Clara, California, and has manufacturing facilities in Cleveland, Ohio, San Diego, Vienna and Singapore. The Company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe, Asia, and Latin America. For more information about Affymetrix, please visit www.affymetrix.com.